Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5IUH

Crystal Structure of the Anaplastic Lymphoma Kinase (ALK) in complex with 5d

Summary for 5IUH
Entry DOI10.2210/pdb5iuh/pdb
Related5IUG 5IUI
DescriptorALK tyrosine kinase receptor, 4-[(4-methylpiperazin-1-yl)methyl]-N-{3-[3-methyl-4-({[5-(propan-2-yl)-1,2-oxazol-3-yl]carbamoyl}amino)phenyl]-1H-pyrazol-5-yl}benzamide (3 entities in total)
Functional Keywordscatalytic domain, transferase
Biological sourceHomo sapiens (Human)
Cellular locationCell membrane ; Single-pass type I membrane protein : Q9UM73
Total number of polymer chains1
Total formula weight37389.86
Authors
Tu, C.H.,Wu, S.Y. (deposition date: 2016-03-18, release date: 2016-05-18, Last modification date: 2024-03-20)
Primary citationTu, C.H.,Lin, W.H.,Peng, Y.H.,Hsu, T.,Wu, J.S.,Chang, C.Y.,Lu, C.T.,Lyu, P.C.,Shih, C.,Jiaang, W.T.,Wu, S.Y.
Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK).
J.Med.Chem., 59:3906-3919, 2016
Cited by
PubMed Abstract: Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available. Herein, we present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type II binding mode. It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK. A structure-activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK. To the best of our knowledge, this is the first structural biology study to directly observe how changes in the structure of a small molecule can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes.
PubMed: 27031565
DOI: 10.1021/acs.jmedchem.6b00106
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

247536

PDB entries from 2026-01-14

PDB statisticsPDBj update infoContact PDBjnumon